|
|
Pulmonary Hypertension - New Potential in a Limited Market.
- Article from:
-
M2 Presswire
- Article date:
-
July 3, 2002
|
Copyright informationCOPYRIGHT 2002 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RDATE:07022002
Pulmonary hypertension is a niche market that has, up until recently, been largely neglected in terms of the development of practical treatments.
However, the number of promising compounds now in late stage development, as evidenced by the filing of the first endothelin receptor antagonist, Tracleer (bosentan), in Europe in February 2001, provides an ideal opportunity to assess the future prospects of this market.
This brief discusses some of the major issues within the pulmonary hypertension market and outlines possible future developments.
So, what do you get from this report?
Pulmonary Hypertension - New Potential in a Limited ...